S-based biotechnology company Alltrna is developing transfer RNA (tRNA)-based therapies that aim to offer a broad solution for thousands of rare genetic diseases by targeting common mutations rather than addressing each disease individually.
The goal of the approach is to overcome the limitations of traditional rare disease therapies, which typically focus on single diseases, making it difficult to develop treatments for the vast majority of rare genetic conditions.
Currently, only 5% of the known genetic diseases have an US Food and Drug Administration (FDA)-approved therapy, according to rare disease non-profit organisation Global Genes. Alltrna’s approach seeks to change this by focusing on nonsense mutations – premature stop codons – which occur in about 10% of genetic diseases and impact an estimated 30 million people worldwide, according to Alltrna’s CEO Michelle Werner.
“In the rare disease setting, there are somewhere around 10,000 different genetic conditions. Even with novel technologies like gene therapy, gene editing, or mRNA, each must address a specific gene or disease,” said Werner. “That’s why only 5% of these diseases have an approved therapy – most remain overlooked and underserved.”
Alltrna’s engineered tRNA technology is designed to read through premature stop codons and restore normal protein production. These specific mutations are found across a range of genetic diseases, making a mutation-focused approach potentially more efficient than developing separate therapies for each disease, explained Werner.
“Our engineered tRNAs can be used across multiple diseases, genes, and mutation locations”, Werner explained. “This represents a far more universal tool to treating patients by taking a mutation-specific approach, rather than a disease-specific approach.”
In December 2024, Alltrna presented preclinical data on its first tRNA candidate, AP003. The chemically modified, engineered tRNA, delivered via a lipid nanoparticle, demonstrated in vivo restoration of protein production in mouse models of two stop codon diseases, methylmalonic acidaemia (MMA) and phenylketonuria (PKU).
One of the interesting parts of Alltrna’s approach is the potential to study these therapies in basket trials, which can group patients with different diseases but with the same underlying genetic mutation. This trial design is commonly used in oncology but has been less explored in rare diseases.
“We’re really working through what that preclinical data package needs to be in order for us to support a broad number of diseases to be included in that basket trial,” highlighted Werner.
She said that Alltrna is working closely with global regulators, including the FDA and European Medicines Agency (EMA), to navigate the complexities of designing such trials. Regulators recognise the challenges of drug development for ultra-rare patients and are encouraging strategies that can address multiple diseases at once, Werner noted.
Other companies are also developing therapies using this approach. In March 2023, Tevard Biosciences entered a four-year global research collaboration with Vertex Pharmaceuticals to develop novel tRNA-based treatments for Duchenne muscular dystrophy caused by nonsense mutations.
Check out our mRNA service to expedite your vaccine research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Nanoscope Therapeutics Publishes Breakthrough Clinical Data Demonstrating Significant Vision Restoration in Retinitis Pigmentosa with Novel AAV-based MCO-010 Gene Therapy
Nanoscope Therapeutics has announced the publication of highly encouraging Phase 1/2a clinical trial data in the esteemed journal Molecular Therapy, showcasing significant vision restoration in patients suffering from retinitis pigmentosa (RP), a debilitating...
Capsida’s AAV CAP-004 Gene Therapy Shows Promise for Friedreich’s Ataxia in Primate Study at MDA Conference
Capsida Biotherapeutics' experimental gene therapy, CAP-004, for Friedreich's ataxia (FA), has demonstrated promising preclinical results in nonhuman primates. Research presented by Capsida at the 2025 MDA Clinical & Scientific Conference showed that a single...
FDA Grants Fast Track to Sanofi’s Chlamydia mRNA Vaccine
Sanofi is making significant strides in the fight against chlamydia, the most common sexually transmitted bacterial infection, for which there are currently no approved preventative vaccines. The French pharmaceutical group has recently been granted a fast-track...
Epicrispr Biotechnologies Announces $68M Series B to Advance First-in-Class FSHD Epigenetic Therapy to Clinic
Epicrispr Biotechnologies today announced the first close of its Series B financing, securing $68 million to support the clinical development of EPI-321, a first-in-class, disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD), a genetic...
Related Services
AAV Packaging Services
READ MORE
Off-the-Shelf AAV Products
READ MORE
